Evidence map›Paper›PMID 26908742›Full record

Trial reportThe Journal of infectious diseases2016

A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.

Anna P Durbin, Beth D Kirkpatrick, Kristen K Pierce, Marya P Carmolli, Cecilia M Tibery, Palmtama L Grier, Noreen Hynes, Kari Opert, Adrienne P Jarvis, Beulah P Sabundayo and 10 more

Registry-linked trialAbstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01782300 (A Phase 1 Evaluation of the Safety and Immunogenicity of a Booster Dose of TV003 Administered 12 Months After Initial Vaccination With TV003), which is not on this map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01782300 phase1completednot on this map

A Phase 1 Evaluation of the Safety and Immunogenicity of a Booster Dose of TV003 Administered 12 Months After Initial Vaccination With TV003

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2013 to 2016Enrolled48ConditionsDengueArmsTV003 Vaccine, Placebo Vaccine
3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. T Cell Responses During Dengue Infection.Current topics in microbiology and immunology · 2026
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Anna P DurbinCenter for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
Beth D KirkpatrickVaccine Testing Center, University of Vermont College of Medicine, Burlington.
Kristen K PierceVaccine Testing Center, University of Vermont College of Medicine, Burlington.
Marya P CarmolliVaccine Testing Center, University of Vermont College of Medicine, Burlington.
Cecilia M TiberyCenter for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
Palmtama L GrierCenter for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
Noreen HynesCenter for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
Kari OpertCenter for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
Adrienne P JarvisVaccine Testing Center, University of Vermont College of Medicine, Burlington.
Beulah P SabundayoCenter for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
Benjamin D McElvanyVaccine Testing Center, University of Vermont College of Medicine, Burlington.
Eli A SendraVaccine Testing Center, University of Vermont College of Medicine, Burlington.
Catherine J LarssonVaccine Testing Center, University of Vermont College of Medicine, Burlington.
Matthew JoCenter for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
Janece M LovchikCenter for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
Catherine J LukeLaboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland.
Mary C WalshVaccine Testing Center, University of Vermont College of Medicine, Burlington.
Ellen A FraserVaccine Testing Center, University of Vermont College of Medicine, Burlington.
Kanta SubbaraoLaboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland.
Stephen S WhiteheadLaboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland.

Funding

Clinical Trials of Biodefense Vaccines (Dengue, West Nile Virus, TBEV)ZIAAI000987 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WHITEHEAD, STEPHEN · 2009 to 2025
$37.9M
NIAID NIH HHS HHSN272200900010C
6 · The paper itself

Abstract

unlabelledThe ideal dengue vaccine will provide protection against all serotypes of dengue virus and will be economical and uncomplicated in its administration. To determine the ability of a single dose of the live attenuated tetravalent dengue vaccine TV003 to induce a suitable neutralizing antibody response, a placebo-controlled clinical trial was performed in 48 healthy adults who received 2 doses of vaccine or placebo administered 12 months apart. Evaluation of safety, vaccine viremia, and neutralizing antibody response after each dose indicated that the first dose of vaccine was capable of preventing infection with the second dose, thus indicating that multiple doses are unnecessary. CLINICAL TRIALS REGISTRATION: NCT01782300.

Indexed as

AdultAntibodies, NeutralizingAntibodies, ViralDengueDengue VaccinesDouble-Blind MethodHumansImmunization ScheduleNational Institute of Allergy and Infectious Diseases (U.S.)PlacebosUnited StatesVaccines, AttenuatedAntibodies, NeutralizingAntibodies, ViralDengue VaccinesPlacebosVaccines, Attenuatedclinical trialdengue vaccinelive attenuated tetravalent

Identifiers

PMID26908742
PMCPMC4996143

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.